BioPharmSignal logoBioPharmSignal

Biotech News

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Biodesix (BDSX)BiodesixPartnership

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment

Related news

BJDXBluejay Diagnostics2026-09-08 10:30 EST

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BDSXBiodesix2026-10-19 20:01 EST

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

BDSXBiodesix2026-04-06 15:43 EST

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

BIAFbioAffinity Technologies, Inc.2026-09-30 12:00 EST

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

BIAFbioAffinity Technologies, Inc.2026-07-22 12:08 EST

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

LUCDLucid Diagnostics2026-09-22 11:55 EST

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

DGXQuest Diagnostics2026-08-24 11:24 EST

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

DGXQuest Diagnostics2026-06-29 12:16 EST

Quest Diagnostics Foundation Commits Nearly $5 Million to Improving Health Outcomes and Food Security in Miami-Dade County, Florida

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

View all latest news

Biodesix

Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations. Diagnostic Testing The company provides blood-based and...

Recent company news

BDSXBiodesix2026-10-22 10:00 EST

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

BDSXBiodesix2026-10-19 20:01 EST

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

BDSXBiodesix2026-10-19 10:00 EST

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

BDSXBiodesix2026-10-13 10:00 EST

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

BDSXBiodesix2026-09-24 10:00 EST

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Stock data

Close
23.94 USD
Market cap
159.89M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States